Replies to post #13118 on OncoSec Medical Inc (ONCSQ)

[Jumpinjackas]

How does cr go from 39% to 12%?

[lasers]

zoriden excellent bravo!!!Regression of non-injected lesions was seen in 62% (13/21) of pts with evaluable lesions.

Results: 29 pts have been enrolled and have received at least one treatment cycle. The ORR is 33% (9/27), with 11% CR (3/27). Regression of non-injected lesions was seen in 62% (13/21) of pts with evaluable lesions. Transient pain (56.5%) and inflammation (17.4%) at the treatment site were the most common grade 1/2 drug-related adverse events (AEs), with no grade 3/4 drug-related AEs. Exploratory analyses indicate a doubling of intratumoral NK cells from pre-treatment through day 11 and at day 39, and increased frequency in activated circulating NK cells.